Private practice with Dr Seth Bilazarian

View all posts »

Smoking electronic cigarettes: A reasonable harm-reduction and smoking-cessation strategy?

Jun 22, 2012 11:05 EDT


They've been around for less than a decade and have grown in popularity thanks to claims that "vaping" is healthier than smoking cigarettes, but what exactly are electronic cigarettes?

To download Dr Seth Bilazarian's presentation, click here.








Your comments
Smoking electronic cigarettes: A reasonable harm-reduction and smoking-cessation strategy?
# 1 of 4
June 22, 2012 01:47 (EDT)
James J. King
Chantix (Varenicline) since 2006 or the east European Tabex (Cytisine) used since 1964 are nicotinic acetylcholine receptor binders.
# 2 of 4
July 21, 2012 09:42 (EDT)
DrSethdb

James, I agree with your first choice of Chantix - I have had good success with using it with many inveterate smokers who were motivated to quick.  As yiu may know we don't have Cystine available in the US because it lacks FDA approval.

The NEJM  article on Cystine in smoking cessation demonstrated superiority to placebo but a rate of 8.2% of sustained abstinence.  THis seems lower than the Chantix rates of sustained abstinence in the trials and clincial practice.  Is this your experience?

Thanks for posting

sb

 

# 3 of 4
August 28, 2012 10:43 (EDT)
tink
You know you talk about other methods to quit smoking. But most of them carry a side effects  lable may cause suicidal tendencies.  I have never heard of that with the E-cigarettes.
# 4 of 4
September 5, 2012 05:50 (EDT)
Elaine Keller

Hello Dr. Billazarian: 

Your presentation listed two references, both of which would be classified as commentary or opinion pieces. But the content of your presentation shows that you have given more weight to the "Promise or Peril" piece. The results of over a dozen clinical studies on the use of e-cigarettes have been published or presented at conferences such as the Society for Research on Tobacco and Nicotine (SRNT), European Respiratory Society (ERS) and European Society of Cardiology (ESC). In addition, many researchers and laboratories have tested e-cigarette liquid and vapor and have done a better job of telling the whole truth about their results than the FDA. You have my email address. Drop me a note and I will be happy to send you a copy of CASAA's document, Electronic Cigarette Research, that lists these articles as well as additional opinion/commentary articles and population surveys of e-cigarette consumers.

On Slide 7 the title "Alleged benefits of e-cigarettes" has the word "alleged" underlined for emphasis. Why? Were you trying to convey the impression that all of the points listed are untrue? It only takes common sense to verify the truth of the first four points. The fourth point is half true. E-cigarettes can deliver nicotine effectively, but several studies show that e-cigarettes do not deliver nicotine more rapidly. Part of your last point has been verified by several researchers, as well as by all of the population surveys: the products significantly reduce craving and number of cigarettes smoked; however they don't do it at a level similar to nicotine-replacement products. They work much, much better. People who tried to quit over 10 times and kept relapsing have been able to finally escape from inhaling tar, CO, numerous toxins, and large particulates along with their nicotine by switching to an e-cigarette.

Slide #8 illustrates how heavily you relied on the "Promise or Peril" opinion piece as your source. For example, the FDA did not find any carcinogens in quantities that exceed the levels in approved NRT products. In fact, extensive testing of vapor has found only a handful of potential toxins in quantities less than 1% of OSHA Permissible Exposure Level. Your drinking water probably has higher numbers and levels of toxins. There is absolutely no evidence that particles of vapor have the same effect as second-hand smoke. As for evidence of a cessation strategy, the published population studies show that 40 to 70% of users have quit smoking. But pay particular attention to the clinical trials conducted by Dr. Riccardo Polosa. He's shown that these products can induce quitting in smokers who had no intention of doing so. Finally, there's a growing body of harm-reduction evidence, including the presentation at the ESC conference by Dr. Konstantinos Farsalinas, and covered by MedScape.

Who am I? Just a 66 year old woman who smoked for 45 years and gave up on giving up over 20 years ago after I became abstinent from nicotine and waited over 6 months for my attention deficits and memory impairments to go away. They didn't. E-cigarettes allowed me to finally stop smoking without having to sacrifice my cognitive health. I've been smoke-free for over 3 years now; and despite continued use of an e-cigarette, I have seen significant improvement in my lung health and markers of CV health (lower cholesterol and lower BP). 

I am an unpaid volunteer for a non-profit organization formed by former smokers who became free from smoke by switching to e-cigarettes and/or smoke-free tobacco products:  The Consumer Advocates for Smoke-free Alternatives Association (CASAA.org). I look forward to corresponding with you.

--Elaine Keller

 


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.

Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.

Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:

  • Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
  • Practice approaches to the extra clinical issues in dealing with managed care insurers
  • Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
  • Experiences with restrictions on testing and imaging
The video blog (VLOG) will provide an opportunity to share broadly different approaches to the common conundrums we face in caring for patients. My hope is that this forum will provide useful data points for practice outside of tertiary and academic centers and a look inside community hospitals and physician?s practice patterns in the office, starting with mine.